The CoVIg3 project aims to develop a point-of-care rapid test based on lateral flow technology for the qualitative detection of antibodies generated by the humoral response in patients exposed to coronavirus (SARS-Cov-2), whether asymptomatic or having contracted the disease with varying levels of severity. The test will simultaneously carry out a multiplexed analysis of IgA, IgM, and IgG immunoglobulins independently in a single device. The test to be developed will have high sensitivity and specificity levels, a fast response time (15 min), and a low cost.

Secondly, the aim is to analyse the genetic profiles of the Human Leukocyte Antigen (HLA) involved in the response to infections in order to find haplotypes with sensitivity/resistance to infection, as well as possible predictors of the evolution of the disease in its varying levels of severity.